Johnson & Johnson

Johnson & Johnson faces shareholder scrutiny over patent litigation, executive pay and IP risk. Learn how board actions could reshape investor confidence and long‑term value.

Johnson & Johnson’s latest market moves, Supreme Court rulings on drug‑pricing law, and clinical‑trial milestones—why investors keep a close eye on this pharma powerhouse.

Johnson & Johnson’s latest earnings reveal solid growth, a stronger dividend and investor confidence—yet regulators, competition and margin pressure could test the health‑care titan’s future.

Johnson & Johnson highlights U.S. innovation as a key driver to boost drug development, market access, and M&A in the biopharma sector, tackling patent cliffs and competition.

Johnson & Johnson’s Generation Fine campaign redefines depression care with patient‑centered dialogue, real‑world tools, and personal stories, while reaffirming 2026 financial guidance.

Johnson & Johnson’s Q1 2026 update shows Stelara’s oral peptide boost, IBD phase‑3 wins and strong financial turnaround, positioning J&J for long‑term growth in psoriasis and gut biotech.

Johnson & Johnson cuts clinical‑documentation time from 700 hrs to 15 mins with AI, slashing costs and speeding drug launches – investors see a modest, optimistic uptick.

Johnson & Johnson’s latest Q1 filing shows steady growth and new sustainability partnership with SPIE, while the FDA’s approval of the ETHICON 4000 surgical stapler highlights cutting‑edge innovation and lower complication rates.

Johnson & Johnson beats earnings expectations with AI‑driven heart imaging and VARIPULSE therapy, boosting dividends and European production while driving med‑tech growth.

Johnson & Johnson’s Q1 earnings reveal steady growth, strategic wins in psoriasis, CAR‑T, and digital health, and a resilient outlook amid biosimilar pressures.